CordenPharma, a CDMO focused on peptides and peptide-based therapeutics, announced a partnership with Viking Therapeutics.
Partnership is expected to support Phase III development of VK2735 in patients with obesity and metabolic disorders amid increasing demand for GLP-1 therapy.
Viking Therapeutics (NasdaqCM:VKTX) experienced a share price increase of 10% last week, coinciding with the announcement of a multi-year manufacturing agreement with CordenPharma for its V2735 ...
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.
CordenPharma and Viking Therapeutics sign multi-year strategic partnership to support the commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735. CordenPharma provides large-scale ...
The expansion will more than double the existing SPPS reactor capacity at CordenPharma Colorado by adding an additional 25,000 L of SPPS capacity – making it a total reactor capacity of >42,000 ...
With crucial lessons learned from the manufacturing shortages of injectable GLP-1s, experts say securing adequate supply for ...
- CordenPharma amplía su plataforma de péptidos con la construcción de una nueva instalación por valor de más de 500 millones de euros en la región de Basilea (Suiza) ...
BASEL, Switzerland, March 5, 2025 /PRNewswire/ -- Following its 16 July 2024 announcement, CordenPharma is pleased to share significant progress on its growth initiatives with a >€1 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback